- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The Phase 1/2 clinical trial of AVB-500 is being done in combination with durvalumab in patients with ovarian cancer.
Aravive (NASDAQ:ARAV) and AstraZeneca (NYSE:AZN) have announced that a Phase 1/2 clinical trial of AVB-500 study in combination with durvalumab, in patients with recurrent epithelial ovarian cancer has begun and is recruiting patients.
As quoted in the press release:
The clinical trial is jointly funded by Aravive and AstraZeneca.
“GAS6/AXL signaling plays a key role in immune evasion, suggesting that inhibition of this pathway has the potential to augment the anti-tumor effects of an anti-PD-L1 agent to achieve better outcomes for patients,” said Gail McIntyre, Ph.D., chief scientific officer of Aravive. “Consequently, we believe there is a strong mechanistic and clinical rationale for exploring the potential of AVB-500 in combination with a checkpoint inhibitor in the treatment of ovarian cancer.”
This open-label trial will begin with a Phase 1b safety lead-in phase to determine the recommended Phase 2 dose (RP2D) for the combination of AVB-500 and durvalumab. In the Phase 2 portion, eligible subjects will participate in a 6-week monotherapy cycle randomized to either AVB-500 or durvalumab before receiving the combination therapy at the RP2D. Patients will receive treatment until progression or unacceptable toxicity with combination therapy. The study is listed on clinicaltrials.gov NCT04019288.
“There is a significant need for effective treatments that don’t add to the treatment burden for women with ovarian cancer,” said Laura Bonifacio, Pharm.D., Ph.D., vice president of clinical operations at Aravive.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.